International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

F Van Rhee, P Voorhees, A Dispenzieri… - Blood, The Journal …, 2018 - ashpublications.org
Castleman disease (CD) describes a group of heterogeneous hematologic disorders with
characteristic histopathological features. CD can present with unicentric or multicentric …

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

L Zhang, A Zhao, M Duan, Z Li, X Cao… - Blood, The Journal …, 2019 - ashpublications.org
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The
anti–interleukin 6 (IL-6) therapy siltuximab is not available everywhere, and is not effective …

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

F Van Rhee, E Oksenhendler, G Srkalovic… - Blood …, 2020 - ashpublications.org
Castleman disease (CD) includes a group of rare and heterogeneous disorders with
characteristic lymph node histopathological abnormalities. CD can occur in a single lymph …

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

DC Fajgenbaum - Blood, The Journal of the American Society …, 2018 - ashpublications.org
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that
share characteristic lymph node histopathology. Patients of all ages present with either a …

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

F van Rhee, C Casper, PM Voorhees… - The Lancet …, 2020 - thelancet.com
Background Siltuximab is recommended by international consensus as a first-line treatment
for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety …

Idiopathic multicentric Castleman's disease: a systematic literature review

AY Liu, CS Nabel, BS Finkelman, JR Ruth… - The Lancet …, 2016 - thelancet.com
Summary Background Multicentric Castleman's disease describes a group of poorly
understood lymphoproliferative disorders driven by proinflammatory hypercytokinaemia …

Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

F van Rhee, K Stone, S Szmania… - Clinical advances in …, 2010 - europepmc.org
Castleman disease (CD) is a nonclonal lymphoproliferative disorder that can affect single
lymph node stations or, alternatively, can be generalized. Interleukin 6 (IL6) plays a pivotal …

Diagnosis and management of Castleman disease

JD Soumerai, AR Sohani, JS Abramson - Cancer control, 2014 - journals.sagepub.com
Background Castleman disease is an uncommon lymphoproliferative disorder characterized
as either unicentric or multicentric. Unicentric Castleman disease (UCD) is localized and …

Castleman disease

A Carbone, M Borok, B Damania, A Gloghini… - Nature Reviews …, 2021 - nature.com
Castleman disease (CD), a heterogeneous group of disorders that share morphological
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …

Clinical and pathological characteristics of HIV-and HHV-8–negative Castleman disease

LI Yu, M Tu, J Cortes, ZY Xu-Monette… - Blood, The Journal …, 2017 - ashpublications.org
Castleman disease (CD) comprises 3 poorly understood lymphoproliferative variants
sharing several common histopathological features. Unicentric CD (UCD) is localized to a …